drugset / Trial / NCT06868082
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants
Timeline
- Start
- 2025-06-20
- Primary completion
- 2026-02-02
- Completion
- 2026-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solrikitug | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.